Clinical Trial Update: Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies [Phase 2]

View source ↗

Summary

Phase II trial of APL-2 in glomerulopathies completed; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• C3 Glomerulonephritis
• Dense Deposit Disease
• Iga Nephropathy
• Lupus Nephritis
• Membranous Nephropathy

Drugs mentioned

• APL-2 (pegylated C3 inhibitor)

Snippet

Sponsor: Apellis Pharmaceuticals, Inc. | Conditions: IgA Nephropathy, Lupus Nephritis | Phase 2 | Status: COMPLETED | Results posted: 2025-02-13